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Abstract
 .We characterized the L-carnitine transport system which is defective in the kidney of juvenile visceral steatosis JVS
mice by using kidney slices and carnitine-related compounds, and evaluated the influence of the transport defect on the
biosynthetic pathway of carnitine. The JVS mouse transport system defect, calculated as the difference in the transport
 .activity between control and JVS mice, was simulated in control by g-butyrobetaine g-BB and acetyl L-carnitine. g-BB
hydroxylase activity in the liver of JVS mice was double that of control mice, but the hepatic level of g-BB in JVS mice
was lower than in control mice, suggesting that the conversion of g-BB to carnitine is not activated in the liver of JVS mice.
JVS mice showed higher fractional excretions not only of L-carnitine but also of g-BB and acetyl L-carnitine than control
mice, indicating disturbed reabsorption of g-BB and acetyl L-carnitine. The disturbed reabsorption of g-BB in JVS mice is
consistent with the fact that the amount of urinary g-BB in JVS mice was four times that of control. The sum of the
concentrations of L-carnitine, acetyl L-carnitine and g-BB in the urine of JVS mice was not significantly different from that
of the control, suggesting no remarkable increase of biosynthesis of g-BB and carnitine in JVS mice. All these findings
suggest that the carnitine transport system plays a role in the transport of g-BB and that carnitine deficiency is aggravated
by the disturbed reabsorption of g-BB in the kidney. q 1998 Elsevier Science B.V.
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1. Introduction
w xIn 1988, Koizumi et al. 1 reported a C3H.OH
 O.formerly named C3H-H-2 strain of mouse in which
microvesicular fatty infiltration of viscera was trans-
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mitted in an autosomal recessive fashion, and they
 . w xnamed it juvenile visceral steatosis JVS mouse 2 .
JVS mice have severe lipid accumulation in the liver,
hypoglycemia, hyperammonemia, growth retardation,
w xcardiac hypertrophy 3 , and abnormal mitochondrial
w xstructure in the muscles 4 , all of which are caused
w xby systemic carnitine deficiency 5 . Administration
w xof L-carnitine suppressed the cardiac hypertrophy 3
and normalized the suppressed expression of the urea
w xcycle enzyme genes 6 which is the cause of hyper-
w xammonemia 7–9 . We, therefore, consider JVS mice
a useful animal model for studying the role of carni-
tine deficiency in pathological conditions.
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We showed that JVS mice most probably have a
genetic defect in the renal carnitine transport system
and that the transport system defect in JVS mice has
 .a high affinity for L-carnitine K value is 58 mMm
w x w x10 . Recently, Kuwajima et al. 11 reported that
carnitine transport activity is also defective in the
fibroblast cells of JVS mice. However, the transport
system defect in JVS mice has not been sufficiently
evaluated for its role in carnitine deficiency. In this
report, we describe the renal carnitine transport sys-
tem and evaluate the significance of the defect on the
biosynthesis of carnitine in JVS mice.
2. Materials and methods
2.1. Animals
JVS mice were originally supplied by Dr. J.
 . w xHayakawa Kanazawa University, Japan 1 . Ho-
 .mozygous mutants JVSrJVS and homozygous con-
 .trols qrq of C3HPOH mice at 3 months of age
were used as JVS and control, respectively. Samples
of urine and serum were collected from the mice
which were kept in metabolic cages from 1900 to
0700 without feeding or light. This study was carried
out according to the Guide for Animal Experimenta-
tion, Faculty of Medicine, Kagoshima University.
2.2. L-carnitine transport acti˝ity in ˝itro
The mice were killed by decapitation and the
kidneys were immediately removed. Total and Na-in-
dependent transport activities in the kidney slices
were measured at 145 mM of Na-ion, and 120 mM of
Li- and 25 mM of K-ions, respectively, as described
w xpreviously 10,12 . The Na-dependent transport activ-
ity was represented as the difference between total
and Na-independent activities. We measured the ac-
tivities at 40 mM of L-carnitine with and without 1
mM of carnitine-related compounds used as in-
hibitors.
2.3. Concentrations of L-carnitine, acetyl L-carnitine
( )and g-butyrobetaine g-BB in the serum, urine, li˝er
and muscle and their fractional excretion
L-carnitine, acetyl L-carnitine and g-BB in serum,
urine, liver and thigh muscle were assayed according
w xto the HPLC method 13 with some modifications to
 .improve sensitivity. Serum 0.4 ml was diluted with
1.0 ml of distilled water and 0.1 ml of 5 mgrml of
carboxypropyl-1-dimethylammonium chloride
 .DMEC: Earth Chemical, Akou, Japan as an internal
 .standard, and urine 0.1 ml , with 1.3 ml water and
0.1 ml of 5 mgrml of DMEC. The diluted serum
specimens were filtered through ultrafiltration filter
Millipore Molcut II. Liver and muscle were homoge-
nized with 5 volumes of 6% perchloric acid, and the
homogenate was centrifuged at 12,000=g for 10
 .min. The supernatant 400 ml was diluted with 1 ml
of water and 0.1 ml of 5 mgrml of DMEC. The
filtrate and the diluted supernatant were purified with
three kinds of ion exchange resin before reversed-
 .phase HPLC analysis as follows: samples 1 ml were
applied to tandem columns A and B, in which eluate
from column A directly flowed into column B. Col-
 .umn A diameter, 0.75 cm was composed of AG1-X8
 y . 100-200 mesh, OH form in the upper part 3.5
. cm and Bio-Rex70 100–200 mesh, pyridine form,
.  .pH 6.7 in the lower part 1 cm , and column B
 . 3.5=0.5 cm was composed of AG50W-X8 200–
.400 mesh, pyridine form, pH 2.5 . The columns were
then washed with 15 ml of water. After washing,
column B was eluted with 4 ml of 5% pyridine. The
eluate was dried with Speedvac Concentrator. The
residue was dissolved with 10 ml of 200 mM potas-
sium phosphate and mixed with 0.5 ml of acetonitrile
containing 2.5 mg of p-bromophenacyl bromide and
 .0.5 mg of 18-crown-6 Aldrich, Milwaukee, USA .
The mixture was ultrasonicated for 10 min, heated for
30 min at 808C, and then dried under nitrogen gas.
The residue was mixed with 0.2 ml of 0.1 M phos-
phoric acid and 1 ml of chloroform. After centrifuga-
tion at 3000 rpm for 10 min, 20 ml layer of water
was injected to an Inertsil ODS-2 column 5 mm,
.10=4.6 mm; GL Sciences, Tokyo, Japan which
was maintained at 408C as part of an LC-6A HPLC
 .system Shimadzu, Kyoto, Japan . The mobile phase
was composed of 75 parts of 5 mM sodium dihydro-
genphosphate, 5 mM phosphoric acid and 100 mM
sodium perchlorate, and 25 parts of acetonitrile. The
flow rate was set at 1.2 mlrmin and peaks were
recorded at 262 nm. Serum data are shown in Fig. 1.
The base-line is flat and g-BB peak is clearly sepa-
rated from other peaks. The limit of this method for
g-BB is 0.5 nmolrml of original solution, indicating
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Fig. 1. Representative data of serum L-carnitine, acetyl L-carni-
tine and g-BB analyzed by HPLC. Serum specimens taken from
 .  .control A and JVS B mice were analyzed as described in
Section 2. Ordinate: absorbance at 262 nm; abscissa: retention
time. g-BB and DMEC denote g-butyrobetaine and car-
boxypropyl-1-dimethylammonium chloride used as internal stan-
dard, respectively.
that this method is reliable for the present experi-
ments.
Creatinine was measured by the enzymatic method
w x14 modified as follows: The serum samples were
filtered through Millipore filters, Ultra Free C3-GC
 .Millipore, Japan , to suppress the background in the
assay. Fractional excretion of carnitine and carnitine-
related compounds was calculated as in our previous
w xreport 10 .
2.4. g-BB hydroxylase acti˝ity
The liver was homogenized with four volumes of
homogenate buffer 0.25 M sucrose and 2 mM Tris–
.HCl, pH 7.5 . The homogenate was centrifuged at
105,000=g and the supernatant was used for the
enzyme assay. We determined g-BB hydroxylase ac-
tivity by measuring carnitine formed from g-BB us-
w xing an isotopic method 15,16 .
2.5. Statistics
Data were analyzed statistically by the unpaired
t-test with the level of significance set at p-0.05.
3. Results and discussion
3.1. Inhibition of renal carnitine transport acti˝ity by
carnitine-related compounds
To characterize the nature of the JVS carnitine
transport system defect, we tested the effect of carni-
tine-related compounds on carnitine transport activity
by using kidney slices. As shown in Fig. 2, total
transport activity in control mouse kidney was
strongly inhibited by acetyl L-carnitine, g-BB and
D-carnitine, but only slightly by g-aminobutyric acid
 .GABA and not at all by choline. The results pre-
sented here are very similar to those obtained with rat
w x w xkidney slices 12 , renal brush-border membrane 17
and Xenopus oocyte injected with RNA from rat
w xrenal cortex 18 , suggesting that our slice system is
valid as an assay method for carnitine transport and
can discriminate the carnitine transport system from
w x w xGABA 19 or choline 20 transporters. The total
 .Fig. 2. The effect of carnitine-related compounds on total left
 .and Na-dependent right carnitine transport activities of kidney
slices from control and JVS mice. Control and JVS mice are
shown as open and shaded columns. Four mice were used in each
 .experiment except control without inhibitors ns7 . Transport
activity was measured at 40 mM of L-carnitine. All of the
 .inhibitors carnitine-related compounds were used at 1 mM. All
data are given as mean"SD. Statistically significant difference
vs. control or JVS mice without inhibitors. )p-0.05; ))p-
0.01. Statistically significant difference vs. indicated pairs. ap-
0.05; aap-0.01; NS, not significant. g-BB and GABA denote
g-butyrobetaine and g-aminobutyric acid, respectively.
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activity of carnitine transport in JVS mice was about
 .32% of control without inhibitors Fig. 2 . Total
activity in JVS mice was slightly inhibited by acetyl
L-carnitine and g-BB, but not by D-carnitine, GABA
or choline. The residual activities in control mouse
kidney determined with acetyl L-carnitine or g-BB
were not different from those of JVS mice without
inhibitors and were slightly higher than those of JVS
mice with inhibitors.
Very similar results were obtained in the Na-de-
pendent activities. The basal activity of JVS mice
was about 20% of the control, and was inhibited
significantly by g-BB, but not by acetyl L-carnitine.
There were no differences between control and JVS
mice in the activities with the inhibitors. The differ-
ences between control and JVS mice in total and
Na-dependent activity the transport activity defect in
. y1 y1JVS mice were 35.0 and 27.8 pmol min mg of
protein, respectively. The values with acetyl L-carni-
tine, similarly calculated, were 3.9 and 0.8 pmol
miny1 mgy1, and the values with g-BB, 3.9 and 0.8
pmol miny1 mgy1, respectively. This indicates that
the transport system defect in JVS mice is simulated
by acetyl L-carnitine and g-BB, and has strong Na-
dependency, and suggests that the transporter for
carnitine plays a role in the reabsorption of acetyl
L-carnitine and g-BB.
3.2. Serum and urinary concentrations of carnitine,
acetyl L-carnitine and g-BB, and their reabsorption
in kidney
To test the above hypothesis, we determined the
concentrations of L-carnitine, acetyl L-carnitine and
g-BB in the serum and urine of JVS and control
mice, and calculated their reabsorptional efficiencies.
Since JVS mice showed no abnormal urinary acylcar-
w xnitine excretion 10 , we identified and measured
acetyl L-carnitine as an acylcarnitine together with
free L-carnitine and g-BB using the HPLC method.
w xAs reported previously 5 , the serum concentration
of L-carnitine is much lower in JVS mice than in
 .control mice Table 1 . Its urinary concentration,
expressed as nmolrmg creatinine, was lower in JVS
mice than in control mice, while there was no signifi-
cant difference in the amount of creatinine excreted
 .between control 104"54 mgr12 h, ns5 and JVS
 .mice 139"33 mgr12 h, ns3 . Fractional excre-
Table 1
Concentrations of L-carnitine, acetyl L-carnitine and g-BB in
serum and urine, and fractional excretion in control and JVS mice
at 3 months of age
Control JVS
L-carnitine
)) .  .  .serum mM 29.4"4.7 3 2.3"0.7 3
)) .  .  .urine nmolrmg Cr 1510"347 5 812"71 3
)) .  .  .fractional excretion % 6.0"0.5 3 42.3"6.3 3
Acetyl L-carnitine
)) .  .  .serum mM 4.6"0.8 3 1.0"0.5 3
)) .  .  .urine nmolrmg Cr 76"44 5 167"41 3
)) .  .  .fractional excretion % 2.9"2.8 3 22.1"6.7 3
g -BB
NS .  .  .serum mM 0.93"0.25 3 1.03"0.10 3
)) .  .  .urine nmolrmg Cr 109"53 5 490"27 3
) .  .  .fractional excretion % 16.6"9.3 3 56.1"14.6 3
Sum of L-carnitineq acetyl L-carnitineqg -BB in urine
NS .  .  .urine nmolrmg Cr 1690"374 5 1470"134 3
All data are given as mean"SD.
Statistically significant difference vs. control: )p-0.05; ))p-
0.01.
NSsnot significant.
The number of samples is shown in parentheses.
Cr denotes creatinine.
tion of L-carnitine, calculated from serum and urinary
concentrations of L-carnitine and creatinine, was much
higher in JVS mice than in control mice, indicating
that reabsorptional efficiency of L-carnitine in the
w xkidney is severely affected in JVS mice 10 .
Serum acetyl L-carnitine concentration was lower
in JVS mice than in control, but urinary concentration
was higher. The fractional excretion of acetyl L-
carnitine in JVS mice was much higher than in
control mice, indicating that reabsorption of acetyl
L-carnitine in JVS mice is also affected.
We measured serum and urinary concentration of
g-BB, the direct precursor of carnitine biosynthesis.
The serum concentration of g-BB in JVS mice did
not differ from control mice. Urine g-BB was about
four times higher in JVS mice than in control, and
fractional excretion was about three times higher in
JVS mice, indicating that the reabsorption of g-BB in
kidney is impaired, or that g-BB to be converted to
L-carnitine leaked from the kidney. Less carnitine
was excreted in JVS mice urine mainly because less
g-BB was converted into carnitine, and also partly
because more carnitine was in the form of acetyl
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 .L-carnitine than control Table 1 . All these results
strongly suggest that the renal carnitine transport
system defect in JVS mice plays a role in the trans-
port of g-BB and acetyl L-carnitine as well as of
L-carnitine.
3.3. Acti˝ity of g-BB hydroxylase in li˝er
L-Carnitine is obtained by dietary intake or en-
dogenously synthesized from trimethyllysine via g-
BB. The final step in the biosynthesis is the conver-
sion of g-BB to L-carnitine by the catalytic action of
g-BB hydroxylase in the liver. To assess the biosyn-
thetic activity of L-carnitine in JVS mice, we mea-
sured g-BB hydroxylase activity. The hepatic g-BB
hydroxylase activity in JVS mice was 1.33"0.44
y1 y1  .nmol min mg protein ns6 , about twice that
 y1 y1of control 0.72"0.27 nmol min mg protein,
.ns6, p-0.01 . This result suggests the increase of
the biosynthetic pathway of L-carnitine and agrees
with the report that no enzyme defect has been found
in the biosynthetic pathway for carnitine in human
w xsystemic carnitine deficiency 21 .
3.4. Content of g-BB in the li˝er and muscle
Some reports indicate that the rate-limiting factor
in the biosynthesis of carnitine is the availability of
g-BB for g-BB hydroxylase in the liver, not the
w xenzyme activity itself 22,23 . We measured g-BB
content in liver and muscle to evaluate the synthesis
of g-BB and carnitine in these organs. As shown in
Table 2, g-BB in the liver of JVS mice was less than
one-half of that in control. On the other hand, g-BB
in the muscle of JVS mice was four times higher than
in control.
Since there was no difference in the concentration
 .of g-BB in the serum Table 1 , we hypothesize that
JVS mice suffer from impaired release of g-BB from
muscle and impaired uptake into the liver, resulting
in impaired availability of g-BB for carnitine synthe-
sis. The higher content of g-BB in the muscle of JVS
mice may imply activated biosynthesis or some ab-
normality in membrane transport because liver con-
tent is lower. Concerning the former, we note that the
sum of L-carnitine, acetyl L-carnitine and g-BB in the
urine of JVS mice was not significantly different
 .from control Table 1 , suggesting that there is no
Table 2
Contents of L-carnitine and g-BB in liver and muscle of control
and JVS mice at 3 months
Control JVS
Li˝er
L-carnitine
))nmolrg 493"62 16.2"7.2
))nmolrorgan 563"101 24.6"10.1
g-BB
))nmolrg 10.5"2.9 3.2"1.1
))nmolrorgan 12.1"4.1 4.9"1.7
Muscle
L-carnitine
))nmolrg 393"52 3.6"0.6
g-BB
))nmolrg 12.1"1.2 50.6"5.1
All data are given as mean"SD of four samples.
Statistically significant difference vs. control: ))p-0.01.
remarkable increase in the biosynthesis of carnitine
and g-BB.
In conclusion, we propose that the carnitine defi-
ciency of JVS mice is primarily caused by abnormal
reabsorption of carnitine, and is at the same time
aggravated by disturbed renal reabsorption of the
biosynthetic precursor, g-BB. It is still possible that
the biosynthesis of g-BB is increased, but we think it
is also possible that, even if it is increased, such an
increase would fail to compensate for carnitine defi-
ciency because of the disturbed renal reabsorption of
g-BB. The results obtained in the present paper are
important for elucidating the pathogenesis of carni-
tine deficiency in humans.
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